Nifty
:
18142.10
Sensex
:
60863.79
-36.00 (-0.20%)
-59.71 (-0.10%)
Nifty
Sensex
:
:
18142.10
60863.79
-36.00 (-0.20%)
-59.71 (-0.10%)

Cadila Healthcare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
44/99

BSE: 532321 | NSE: CADILAHC

NSE BSE
510.60
21-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  518.35
  •  522.50
  •  505.05
  •  517.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1131700
  •  5798.24
  •  673.70
  •  404.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 52,231.35
  • 23.04
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 55,935.55
  • 0.69%
  • 3.84

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 0.94%
  • 7.38%
  • FII
  • DII
  • Others
  • 4.11%
  • 10.89%
  • 1.80%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.12
  • 10.00
  • 4.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.93
  • 11.92
  • 2.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.32
  • 7.49
  • 5.00

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.98
  • 25.61
  • 24.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.37
  • 4.43
  • 3.52

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.21
  • 16.53
  • 14.10

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
4,025.40
3,514.60
14.53%
3,846.70
3,752.10
2.52%
3,795.60
3,638.10
4.33%
3,820.00
3,366.60
13.47%
Expenses
3,092.40
2,724.10
13.52%
2,991.40
2,960.90
1.03%
2,988.70
2,940.30
1.65%
2,956.60
2,731.00
8.26%
EBITDA
933.00
790.50
18.03%
855.30
791.20
8.10%
806.90
697.80
15.63%
863.40
635.60
35.84%
EBIDTM
23.18%
22.49%
22.23%
21.09%
21.26%
19.18%
22.60%
18.88%
Other Income
31.60
22.50
40.44%
-40.30
44.30
-
27.50
20.10
36.82%
27.50
26.90
2.23%
Interest
27.30
67.70
-59.68%
23.30
82.50
-71.76%
26.80
80.50
-66.71%
45.70
89.70
-49.05%
Depreciation
182.70
172.80
5.73%
188.60
178.50
5.66%
180.40
174.10
3.62%
179.00
172.30
3.89%
PBT
754.60
572.50
31.81%
530.00
522.00
1.53%
627.20
457.10
37.21%
534.20
122.40
336.44%
Tax
141.50
118.20
19.71%
-201.60
108.50
-
114.70
92.70
23.73%
110.60
39.50
180.00%
PAT
613.10
454.30
34.95%
731.60
413.50
76.93%
512.50
364.40
40.64%
423.60
82.90
410.98%
PATM
15.23%
12.93%
19.02%
11.02%
13.50%
10.02%
11.09%
2.46%
EPS
5.73
4.43
29.35%
6.63
3.83
73.11%
5.15
3.65
41.10%
4.62
1.05
340.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
15,487.70
15,102.20
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
Net Sales Growth
8.52%
5.96%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
 
Cost Of Goods Sold
5,335.20
4,472.50
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
Gross Profit
10,152.50
10,629.70
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
GP Margin
65.55%
70.39%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
Total Expenditure
12,029.10
11,763.60
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
Power & Fuel Cost
-
234.50
252.90
231.60
211.40
174.50
155.40
145.40
129.70
124.40
93.40
% Of Sales
-
1.55%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
1.96%
1.77%
Employee Cost
-
2,254.80
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
818.40
679.90
% Of Sales
-
14.93%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
12.87%
12.92%
Manufacturing Exp.
-
2,353.80
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
897.30
718.90
% Of Sales
-
15.59%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
14.11%
13.66%
General & Admin Exp.
-
385.70
582.60
583.40
398.70
466.00
356.40
326.80
302.70
342.20
272.60
% Of Sales
-
2.55%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
5.38%
5.18%
Selling & Distn. Exp.
-
1,477.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
857.50
767.40
% Of Sales
-
9.78%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
13.49%
14.58%
Miscellaneous Exp.
-
584.70
525.90
371.20
404.40
502.60
416.10
330.50
295.20
157.40
767.40
% Of Sales
-
3.87%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
2.48%
3.52%
EBITDA
3,458.60
3,338.60
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
EBITDA Margin
22.33%
22.11%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
Other Income
46.30
44.90
117.10
208.50
133.00
147.10
116.60
57.20
85.90
38.40
53.00
Interest
123.10
168.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
168.70
182.70
Depreciation
730.70
724.80
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
PBT
2,446.00
2,489.90
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
Tax
165.20
147.20
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
Tax Rate
6.75%
6.44%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
PAT
2,280.80
2,086.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
PAT before Minority Interest
2,206.70
2,137.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
Minority Interest
-74.10
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
PAT Margin
14.73%
13.81%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
PAT Growth
73.43%
81.76%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
 
EPS
22.28
20.38
11.21
17.60
16.73
14.20
18.47
11.22
7.85
6.38
6.37

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
Non-Current Liabilities
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
Secured Loans
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
917.20
901.90
Unsecured Loans
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
Long Term Provisions
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
Current Liabilities
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
Trade Payables
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
Other Current Liabilities
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
Short Term Borrowings
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
Short Term Provisions
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
Total Liabilities
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
Net Block
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
Gross Block
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
Accumulated Depreciation
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
Non Current Assets
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
Capital Work in Progress
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
Non Current Investment
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
Long Term Loans & Adv.
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
Other Non Current Assets
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
Current Assets
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
Current Investments
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
Inventories
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
Sundry Debtors
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
Cash & Bank
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
Other Current Assets
1,265.30
441.60
496.00
520.70
348.50
358.90
311.50
323.50
345.90
332.00
Short Term Loans & Adv.
814.90
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
Net Current Assets
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
Total Assets
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
3,293.00
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
PBT
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
Adjustment
1,166.40
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
315.90
320.90
Changes in Working Capital
186.80
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
Cash after chg. in Working capital
3,638.00
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
0.00
-38.80
Cash From Investing Activity
-722.50
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
Net Fixed Assets
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
Net Investments
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
Others
-193.20
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
Cash from Financing Activity
-2,548.90
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
Net Cash Inflow / Outflow
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
Opening Cash & Equivalents
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
Closing Cash & Equivalent
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
ROA
9.37%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
ROE
18.30%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
ROCE
13.65%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
18.21%
24.01%
Fixed Asset Turnover
0.89
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
Receivable days
82.06
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
Inventory Days
72.81
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
Payable days
66.13
64.85
68.81
68.11
74.18
65.30
55.05
49.83
43.54
49.87
Cash Conversion Cycle
88.74
102.77
100.73
78.94
62.42
52.51
61.46
65.78
74.05
72.45
Total Debt/Equity
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
Interest Cover
14.54
5.38
13.17
21.87
26.55
40.75
22.29
8.98
5.79
5.35

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Zydus Cadila gets tentative approval from USFDA for Adapalene and Benzoyl Peroxide Gel
    8th Oct 2021, 15:27 PM

    The drug will be manufactured at the group’s Topical plant at Ahmedabad

    Read More
  • Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose COVID vaccine
    6th Oct 2021, 09:03 AM

    The company has already received the EUA from the DCGI for ZyCoV-D to be administered in three doses on August 20, 2021

    Read More
  • Cadila Healthcare enters into agreement with Shilpa Medicare
    24th Sep 2021, 15:19 PM

    The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties

    Read More
  • Zydus Cadila’s arm gets final approval to market Apremilast Tablets
    24th Sep 2021, 11:15 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets
    18th Sep 2021, 12:10 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets tentative approval from USFDA for Brexpiprazole Tablets
    9th Sep 2021, 14:07 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila’s Sitagliptin base tablets gets tentative approval from USFDA
    6th Sep 2021, 11:26 AM

    Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia

    Read More
  • Zydus Cadila looking to supply COVID-19 vaccine ZyCoV-D by middle to end of September
    23rd Aug 2021, 13:10 PM

    The pricing of the dose will be announced in the next one or two weeks

    Read More
  • Zydus Cadila gets 180-day exclusivity for Tofacitinib extended-release 22 mg tablets
    23rd Aug 2021, 10:52 AM

    Zydus was the first ANDA filer on Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength

    Read More
  • Zydus Cadila receives EUA from DCGI for ZyCoV-D
    21st Aug 2021, 09:04 AM

    ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day

    Read More
  • Cadila Healthcare’s arm partners with CHEMI of Italy
    20th Aug 2021, 14:57 PM

    Under the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection which Zydus will commercialize in the US

    Read More
  • Zydus Cadila gets tentative approval from USFDA to market Lenalidomide Capsules
    17th Aug 2021, 16:45 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets final approval from USFDA to market Mesalamine Extended-Release Capsules
    13th Aug 2021, 11:28 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets final approval from USFDA for Fulvestrant Injection
    30th Jul 2021, 13:35 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the Zydus Biologics, Ahmedabad

    Read More
  • Zydus Cadila submits additional data to DCGI for its COVID-19 vaccine
    28th Jul 2021, 12:55 PM

    The drug regulator had asked the pharma major to return with more data

    Read More
  • Zydus Cadila gets tentative approval from USFDA to market Ibrutinib Tablets
    22nd Jul 2021, 10:31 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Cadila Healthcare’s arm completes sale of animal health business for Rs 2,921 crore
    15th Jul 2021, 12:29 PM

    The transaction of sale and disposal is completed /closed on July 14, 2021

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.